拉科萨米德与托皮拉米德在偶发性偏头痛:一个随机对照双盲试验
Mohamed G Zeinhom1, Mohamed Fouad Elsayed Khalil2, Mohamed Almoataz3
1Neurology Department, Faculty of Medicine, Kafr EL Sheikh University, Elgeish Street, Kafr El Sheikh 33511, Egypt.
Therapeutic advances in neurological disorders
|December 12, 2025
概括
拉科萨米德在减少每月偏头痛患者的偏头痛日数方面表现出与托皮拉相似的疗效. 拉科萨米德的耐受性更好,由于不良反应而停止治疗的患者较少.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是一种普遍的头痛疾病,需要预防性治疗,可能有禁忌.
- 拉科萨米德在偏头痛管理中的潜在作用与其与缩蛋白反应介质蛋白2的相互作用有关,影响色素基因相关的释放.
研究的目的:
- 评估lacosamide的疗效和安全性,作为预防偏头痛的托皮拉玛替代品.
- 评估对托皮拉或其他已批准的抗发作偏头痛预防药物有禁忌的患者的拉科萨米德.
主要方法:
- 一个平行组研究,比较lacosamide和topiramate在情节性偏头痛患者 (18-65岁).
- 剂量:拉科萨米德每天50毫克1周,然后每天100毫克90天;托皮拉每天50毫克1周,然后每天100毫克90天.
主要成果:
- 在每月偏头痛天数 (MMD) 的绝对变化中,在lacosamide和topiramate组之间没有显著差异 (p=0.34).
- 患者在偏头痛日减少≥50%的比例相似 (p=0.11).
- 与托皮拉 (8.0%) 相比,由于副作用而停止服用拉克萨米德的患者较少 (4.7%),这表明耐受性更好 (p=0.03).
结论:
- 拉科萨米德 (50毫克两次一天3个月) 有效降低了MMD,急性药物使用和头痛影响测试-6分数,与托皮拉相比.
- 与托皮拉相比,拉科萨米德是预防情节性偏头痛的更耐受的选择.
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
851
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
851
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
785
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
785